A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of MIN-101 in Patients With Negative Symptoms of Schizophrenia, Followed by a 24-Week, Open-Label Extension

Trial Profile

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of MIN-101 in Patients With Negative Symptoms of Schizophrenia, Followed by a 24-Week, Open-Label Extension

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs MIN 101 (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Minerva Neurosciences
  • Most Recent Events

    • 31 Jul 2017 Results published in a Minerva Neurosciences Media Release.
    • 28 Jul 2017 Results published in the American Journal of Psychiatry.
    • 13 Mar 2017 According to a Minerva Neurosciences media release, results from the study were presented at the 2016 Annual Meeting of the American College of Neuropsychopharmacology (ACNP).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top